Compare TTMI & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTMI | NTLA |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 986.9M |
| IPO Year | 2000 | 2016 |
| Metric | TTMI | NTLA |
|---|---|---|
| Price | $67.07 | $10.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 22 |
| Target Price | ★ $76.50 | $19.83 |
| AVG Volume (30 Days) | 1.7M | ★ 3.4M |
| Earning Date | 02-04-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.88 | N/A |
| EPS | ★ 1.26 | N/A |
| Revenue | ★ $2,782,990,000.00 | $57,528,000.00 |
| Revenue This Year | $20.48 | $1.96 |
| Revenue Next Year | $9.28 | N/A |
| P/E Ratio | $55.62 | ★ N/A |
| Revenue Growth | 17.88 | ★ 33.52 |
| 52 Week Low | $15.78 | $5.90 |
| 52 Week High | $80.58 | $28.25 |
| Indicator | TTMI | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 59.72 |
| Support Level | $65.20 | $8.94 |
| Resistance Level | $74.74 | $9.62 |
| Average True Range (ATR) | 3.55 | 0.47 |
| MACD | -0.57 | 0.25 |
| Stochastic Oscillator | 33.66 | 90.12 |
TTM Technologies Inc manufactures technology solutions, including mission systems, radio frequency (RF) components/RF microwave/microelectronic assemblies, quick-turn and technologically printed circuit boards (PCB). The company is based in the United States and derives roughly half of its revenue domestically. It organizes itself into two segments: printed circuit boards and RF&S Components. The printed circuit boards segment, which contributes the majority of revenue, offers a range of printed circuit boards as well as layout design and simulation, and testing services. TTM Technologies' products are used in manufacturing, networking, telecommunications, computing, aerospace, and medical fields.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.